摘要
目的探讨湿润暴露疗法/湿润烧伤膏(MEBT/MEBO)作用MMP-2和MMP-9促进慢性创面愈合的机制。方法90只Wistar大鼠随机分为5组:MEBO组、贝复新组、慢性组、急性组和空白组,每组18只,构建慢性难愈合创面模型。采用ELISA、Western blot和qRT-PCR技术,检测d 3、14创面组织中MMP-2和MMP-9表达变化。结果(1)与慢性组相比,MEBO组和贝复新组创面愈合时间明显缩短且愈合率升高(P<0.05);且生长情况及病理形态学改变更好;(2)与慢性组相比,d 3标本匀浆中,MEBO组和贝复新组MMP-2和MMP-9表达均增高(均P<0.05);而d 14,MEBO组和贝复新组MMP-2和MMP-9均降低(P<0.05);(3)与慢性组相比,d 3标本,MEBO组和贝复新组MMP-2和MMP-9表达量均增高(P<0.05);而d 14,MEBO组和贝复新组MMP-2和MMP-9表达均降低(P<0.05)。结论MEBT/MEBO促进慢性创面愈合可能与调控MMP-2和MMP-9,来参与ECM的降解与重塑相关。
Aim To investigate the mechanism of MEBT/MEBO in promoting chronic wound healing by MMP-2 and MMP-9.Methods Ninety Wistar rats were randomly divided into five groups:MEBO group,rb-bFGF group,chronic wound group,acute wound group and blank group.Eighteen rats in each group were modeled as chronic refractory wounds.The expression of MMP-2 and MMP-9 in wound tissues,on 3rd and 14th day,was detected by ELISA,Western blot and qRT-PCR.Results(1)Compared with chronic wound group,the time of wound healing was obviously shorter and the rate of wound healing was higher in MEBO group and rb-bFGF group(P<0.05);meanwhile,the growth of wounds and the pathological changes of wounds were better in MEBO group and rb-bFGF group.(2)On 3rd day,the expression of MMP-2 and MMP-9 in MEBO group and rb-bFGF group was higher than that in chronic wound group(P<0.05);however,on 14th day,the expression of MMP-2 and MMP-9 in MEBO group and rb-bFGF group also decreased(P<0.05).(3)Compared with chronic wound group,the expression of MMP-2 and MMP-9 in MEBO group and rb-bFGF group increased on 3rd day(P<0.05),while the expression of MMP-2 and MMP-9 decreased in MEBO group and rb-bFGF group on 14th day(P<0.05).Conclusions MEBT/MEBO promoting chronic wound healing may be associated with regulating MMP-2 and MMP-9 to participate in the degradation and remodeling of ECM.
作者
陈端凯
冯时
唐乾利
姜艳
唐强
岑小宁
黄汉基
尹星
CHEN Duan-kai;FENG Shi;TANG Qian-li;JIANG Yan;TANG Qiang;CEN Xiao-ning;HUANG Han-ji;YIN Xing(Dept of Clinical Medical,Youjiang Medical University for Nationalities,Baise,Guangxi 533000,China;Dept of Medicine,Guangxi University,Nanning 530004,China;Dept of First Clinical Medical,Guangxi University of Chinese Medicine,Nanning 530001,China)
出处
《中国药理学通报》
CAS
CSCD
北大核心
2020年第2期288-294,共7页
Chinese Pharmacological Bulletin
基金
国家自然科学基金面上项目(No 81774327)
国家自然科学基金地区基金项目(No 81560776)
广西研究生教育创新计划项目(No YCSW2018212)
广西特聘专家'专项经费资助(桂人才通字【2019】13号)。
